InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,612.02
(
1.15%
)
Post# of 363704
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jimmybob

Send PM Follow Ignore
Followers 1880
Posts 137554
Boards Moderated 5
Alias Born 01/03/2007

jimmybob

Re: None

Friday, 10/24/2014 8:43:59 AM

Friday, October 24, 2014 8:43:59 AM

Post# of 363704
Regeneron price target raised to $460 from $350 at Canaccord
Canaccord raised its price target on Regeneron to $460 from $350 to reflect the upside potential of Eylea in Diabetic Macular Edema which was approved by the FDA in July. The firm also noted the sales pace of Lucentis only slowed slightly. Canaccord reiterated its Buy rating on Regeneron shares

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up